Delamanid does not inhibit or induce cytochrome P450 enzymes in Vitro

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 11, 2014, Pages 1727-1735

  Shimokawa, Yoshihiko ^a   Sasahara, Katsunori ^a   Yoda, Noriaki ^a   Mizuno, Katsuhiko ^a   Umehara, Ken ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CYP; CYP induction; CYP inhibition; Delamanid; Drug interaction; OPC 67683

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DELAMANID; DRUG METABOLITE; MESSENGER RNA; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GENETICS; METABOLISM;

ANTITUBERCULAR AGENTS; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; NITROIMIDAZOLES; OXAZOLES; RNA, MESSENGER;

EID: 84910092131     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00311     Document Type: Article

References (28)

1. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015, World Health Organization progress report 2011. WHO/HTM/TB/2011.3.
2. World Health Organization. "WHO report 2011: Global tuberculosis control.": 〈http://whqlibdoc.who.int/publications/2011/9789241564380-eng.pdf〉.
3. Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, De Cock KM, Hankins C, Miller B, Castro KG, Raviglione MC. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect. Dis., 6, 483-495 (2006).
4. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J., 38, 516-528 (2011).
5. Gandhi NR, Andrews JR, Brust JCM, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int. J. Tuberc. Lung Dis., 16, 90-97 (2012).
6. Flockhart DA. "Drug interactions: Cytochrome P450 drug interaction table. [Online] Indiana University School of Medicine (2007).": 〈http://medicine.iupui.edu/clinpharm/ddis/table.aspx〉, cited 14 January, 2014.
7. Guengerich FP, Rendic S. Update information on drug metabolism systems - 2009, Part I. Curr. Drug Metab., 11, 1-3 (2010).
8. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 4, 825-833 (2005).
9. Gengiah TN, Gray AL, Naidoo K, Karim QA. Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin. Drug Saf., 10, 559-574 (2011).
10. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N. Engl. J. Med., 344, 984-996 (2001).
11. Sasaki H, Haraguchi Y, Itotani M, Kuroda H, Hashizume H, Tomishige T, Kawasaki M, Matsumoto M, Komatsu M, Tsubouchi H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1- b]oxazoles. J. Med. Chem., 49, 7854-7860 (2006).
12. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 3, e466 (2006).
13. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis., 15, 949-954 (2011).
14. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med., 366, 2151-2160 (2012).
15. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur. Respir. J., 41, 1393-1400 (2013).
16. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423 (1994).
17. European Medicines Agency. "Guideline on the investigation of drug interactions": 〈http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf〉, cited 2012.
18. Ikeda T, Nishimura K, Taniguchi T, Yoshimura T, Hata T, Kashiyama E, Kudo S, Miyamoto G, Kobayashi H, Kobayashi S, Okazaki O, Hakusui H, Aoyama E, Yoshimura Y, Yamada Y, Yoshikawa M, Otsuka M, Niwa T, Kagayama A, Suzuki S, Satoh T. In vitro evaluation of drug interaction caused by enzyme inhibition. Xenobio. Metabol. and Dispos., 16, 115-126 (2001).
19. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos., 35, 246-255 (2007).
20. Quistorff B, Dich J, Grunnet N. Preparation of isolated rat liver hepatocytes. Methods Mol. Biol., 5, 151-160 (1990).
21. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos., 31, 421-431 (2003).
22. Robertson P, Decory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab. Dispos., 28, 664-671 (2000).
23. LeCluyse EL, Audus KL, Hochman JH. Formation of extensive canalicular networks by rat hepatocytes cultured in collagensandwich configuration. Am. J. Physiol., 266, C1764-C1774 (1994).
24. LeCluyse EL, Bullock PL, Parkinson A, Hochman JH. Cultured rat hepatocytes. Pharm. Biotechnol., 8, 121-159 (1996).
25. Mudra DR, Parkinson A. Preparation of hepatocytes. Curr. Protoc. Toxicol., Chapter 14, Unit 14.2 (2001).
26. Madan A, Dehaan R, Mudra D, Carroll K, LeCluyse E, Parkinson A. Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. Drug Metab. Dispos., 27, 327-335 (1999).
27. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J. Antimicrob. Chemother., 64, 910-928 (2009).
28. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AYH. Human cytochrome P450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos., 28, 360-366 (2000).